scholarly journals Current Anticoagulation Recommendation for COVID-19 Patients

2021 ◽  
Vol 2 (4) ◽  
pp. 1-3
Author(s):  
Indra Prasetya

Thromboembolic events in COVID-19 patients can be one of the factors that aggravate the disease and increase mortality. When severe hypoxemia and hypotension occur in COVID-19 patients, the possibility of embolism should be considered. As a result, anticoagulant therapy in COVID-19 patients has an essential role in lowering disease severity and mortality. Many studies report that giving anticoagulants to COVID-19 patients can reduce mortality. Therefore, it is important to understand the role and use of anticoagulant therapy in cases of COVID-19. Several guidelines that have been issued by several health organizations in the world and Indonesia can be used as guidelines for clinicians to start anticoagulant therapy in cases of COVID-19. Various anticoagulant drug regimens have also been recommended to be used both as prophylaxis and as therapy for thromboembolism that can occur after COVID-19 cases.

2018 ◽  
Vol 2 (9) ◽  
pp. 207-212
Author(s):  
Ritesh Vatsa ◽  
Priyanka Priyadarshini

Periodontists are encountering increasing number of cases in their practices where patients present with cardiovascular diseases. Patients with a history of myocardial infarction, ischaemic stroke, acute coronary syndrome or peripheral vascular disease are prescribed anticoagulant medications by cardiologists, such as aspirin, warfarin, clopidogrel, ticlopidine, prasugrel, dipyridamole, cilostazol or dabigatran- either as monotherapy or dual therapy, for prevention of further thromboembolic events during lifetime. As because these agents act by inhibiting platelet aggregation, they tend to prolong bleeding time. Concerns regarding excessive periprocedural bleeding in patients receiving such drugs have led to some clinicians recommending periprocedural discontinuation of anticoagulant therapy. However, several studies, including systematic reviews and meta-analyses, have proved that there is no significantly increased risk of bleeding associated with continuing anticoagulant therapy when compared with discontinuation or modification of the anticoagulant regimen. In fact, without the anticoagulant medication, these patients have been found to be at increased risk of thromboembolic events with potentially serious consequences. The accepted recommendation, therefore, is that the anticoagulant drug regimens should not be altered or discontinued prior to periodontal treatment procedures, as the risks associated with such discontinuation far outweigh the consequences of prolonged bleeding, which can be well controlled with local measures.


Author(s):  
Marlus Da Silva Pedrosa ◽  
Jézlia Chris Da Silva Galdino ◽  
Flávia Ennes Dourado Ferro ◽  
José Guilherme Férrer Pompeu ◽  
Marcia Socorro da Costa Borba

Introduction: Dental treatment performed in patients on anticoagulant drug therapy is becoming increasingly common in dental offices. Thus, questions concerning thromboembolic and bleeding risks relative to invasive dental procedures, are frequently raised. Aim: To review the scientific evidences regarding anticoagulant therapy interruption in patients taking warfarin undergoing oral surgeries. Methods: It was carried out a literature review in the electronic SciELO, PubMed, Lilacs and Oviatt Library databases from January to March of 2016, using as descriptors: Anticoagulants, Warfarin, Oral Surgery, and Oral Hemorrhage. Results and Discussion: Anticoagulant therapy is extremely important in patients at high risk for development of thromboembolic events. Most studies show that the risk of bleeding oral surgery in patients taking warfarin is relatively insignificant and it can be controlled by simple measures such as hemostasis. Conclusion: It is highly recommended to not interrupt anticoagulant in minor oral surgeries.


Author(s):  
Shinji Kobayashi ◽  
Luis Falcón ◽  
Hamish Fraser ◽  
Jørn Braa ◽  
Pamod Amarakoon ◽  
...  

Objectives: The emerging COVID-19 pandemic has caused one of the world’s worst health disasters compounded by social confusion with misinformation, the so-called “Infodemic”. In this paper, we discuss how open technology approaches - including data sharing, visualization, and tooling - can address the COVID-19 pandemic and infodemic. Methods: In response to the call for participation in the 2020 International Medical Informatics Association (IMIA) Yearbook theme issue on Medical Informatics and the Pandemic, the IMIA Open Source Working Group surveyed recent works related to the use of Free/Libre/Open Source Software (FLOSS) for this pandemic. Results: FLOSS health care projects including GNU Health, OpenMRS, DHIS2, and others, have responded from the early phase of this pandemic. Data related to COVID-19 have been published from health organizations all over the world. Civic Technology, and the collaborative work of FLOSS and open data groups were considered to support collective intelligence on approaches to managing the pandemic. Conclusion: FLOSS and open data have been effectively used to contribute to managing the COVID-19 pandemic, and open approaches to collaboration can improve trust in data.


1999 ◽  
Vol 14 (4) ◽  
pp. 491-522
Author(s):  
Brady Coleman ◽  
Robert Beckman

AbstractIntegrated coastal management (ICM) programmes are being planned, formulated and implemented in coastal States all over the world. To date, however, ICM has been seen as more in the realm of policy-makers, managers, scientists, coastal resource economists, and others, rather than in the realm of lawyers. This article reveals how law and lawyers should play an absolutely essential role at all stages of the ICM process. Ideally, ICM legal consultants will have a broad range of knowledge and experience in both international legal treaties as well as in certain fundamental national law principles, so that coastal zone policies will be designed and carried out with a critical understanding of the laws and institutions needed for the long-term success of an integrated coastal management programme.


Author(s):  
Eddy Gilissen ◽  
◽  
Chris Mulligan ◽  
Simon Tottman ◽  
Per Troein ◽  
...  

Healthcare systems across the world are looking at ways of maintaining the continuity of supply of medicines to patients in times of crisis.Whilst this is not a new phenomenon, the additional burden placed on the supply chain during COVID-19 has meant it has come more into the spotlight. The need to use a stockpile can be caused by an interruption to supply, a rapid and unexpected peak in demand, or when both an interruption to supply and a peak in demand occur simultaneously. The objectives of a stockpile will guide the portfolio breadth and depth to be held. Stockpile objectives are broadly driven either by government requirements to protect public health or by organisations seeking toachieve commercial gain. These drivers are not mutually exclusive as in the case of holding safety stock and Public Service Obligation stock. An Emergency Stockpile is Public Health driven and held in order to supply essential medicines during a signifcant or catastrophic event. Emergency stockpiles can be split into three categories — preparation for imminent event, disease specifc response and general contingency stockpiles. Governments and authorities determine which products and volumes should be held in an emergency stockpile which may be guided by the World Health Organizations (WHO) l ist of essential medicines.


2008 ◽  
Vol 1 (1) ◽  
pp. 2-6 ◽  
Author(s):  
Gwyneth Lewis

Every year some eight million women suffer preventable or remediable pregnancy-related complications and over half a million will die unnecessarily. Most of these deaths could be averted at little or no extra cost, even where resources are limited, but in order to take action, and develop and implement changes to maternity services to save mothers and newborns lives, a change in cultural attitudes and political will, as well as improvements in the provision of health and social care, is required. Further, to aid programme planners, more in-depth information than that which may already be available through national statistics on maternal mortality rates or death certificate data is urgently needed. What is required is an in-depth understanding of the clinical, social, cultural or any other underlying factors which lead to mothers' deaths. Such information can be obtained by using any of the five methodologies outlined in the World Health Organizations programme and philosophy for maternal death or disability reviews, ‘Beyond the Numbers’, briefly described here and which are now being introduced in a number of countries around the world.


2021 ◽  
Vol 12 (7) ◽  
pp. 130-137
Author(s):  
Hosseini Mehr Seyed Pouriya ◽  
Smorzhevskyi Valentyn ◽  
Dzekunova Yuliia ◽  
Dmytrenko Igor

While SARS-CoV-2 infection continues to circulate around the world, there are still many uncertainties on how to treat the patients with this potentially deadly virus, and more importantly, for how long! COVID-19 causes many different symptoms, among which coagulopathy seems to play an essential role in the survival prognosis of patients. While medical centers worldwide have developed various algorithms for preventing thrombosis in COVID-19  patients, there are still no clear guidelines on the length of thromboprophylaxis therapy, target groups who should receive suitable anticoagulant prophylaxis, and even the choice of the most appropriate agent for such treatment.  


2021 ◽  
Vol In Press (In Press) ◽  
Author(s):  
Katayoun Haryalchi ◽  
Abtin Heidarzadeh ◽  
Mahmood Abedinzade ◽  
Sepehr Olangian Tehrani ◽  
Samaneh Ghazanfar Tehran

Background: Nowadays, the new coronavirus (SARS-CoV-2) and its complications are one of the main concerns of the world. One of the most severe complications of COVID-19 is hypoxemia. Objectives: This study aimed to assess the importance of happy hypoxemia in COVID-19. Methods: We systematically searched web of science, PubMed, and Google scholar databases to find articles related to COVID-19 and happy hypoxemia. Results: COVID-19 causes a type of hypoxemia named silent (happy) hypoxemia, which has an atypical clinical presentation. This type of hypoxemia has not been noted before in viral pneumonia, and there is no specific treatment for this serious complication. Patients with silent hypoxemia may develop severe hypoxemia without dyspnea and with near-normal lung compliance. These patients are awake, calm, and responsive. Although their lungs are not oxygenated efficiently, they are alert and cooperative. Their condition may be deteriorated rapidly without warning and causes death. Conclusions: According to the findings, paying attention to happy hypoxemia is important for improving the health status of COVID-19 patients.


Sign in / Sign up

Export Citation Format

Share Document